NCT06192758 - Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

October 31, 2032

Conditions

ProstateCancer

Interventions

DEVICE

TheraSphere PCa

Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).

Trial Locations (5)

10022

Mount Sinai Hospital, New York

10075

Weill Cornell Medicine, New York

33136

University of Miami (Sylvester Comprehensive Cancer Center), Miami

60611

Northwestern Memorial Hospital, Chicago

90095

Ronald Reagan UCLA Medical Center (UCLA Health, Los Angeles), Los Angeles